共 556 条
[1]
Allison KH(2020)Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update J Clin Oncol 38 1346-1366
[2]
Hammond MEH(2022)Impact of human epidermal growth factor receptor 2 (HER2) low status in response to neoadjuvant chemotherapy in early breast cancer Cureus 14 1124-1135
[3]
Dowsett M(2019)Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study Lancet Oncol 20 345-352
[4]
McKernin SE(2010)Strategies and challenges for the next generation of therapeutic antibodies [Review] Nat Rev Immunol 10 398-405
[5]
Carey LA(2011)Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy [Clinical Trial, Phase II Multicenter Study] J Clin Oncol 29 1652-1654
[6]
Fitzgibbons PL(2005)The distinctive nature of HER2-positive breast cancers [Comment] N Engl J Med 353 2639-2648
[7]
Hayes DF(1999)Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease J Clin Oncol 17 155-163
[8]
Lakhani SR(2021)HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer Breast Cancer Res Treat 190 1151-1161
[9]
Chavez-MacGregor M(2021)Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials Lancet Oncol 22 444-453
[10]
Perlmutter J(2020)NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2 [Clinical Trial, Phase III Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't] J Clin Oncol 38 112-370